WG
CLDX icon

Winton Group’s Celldex Therapeutics CLDX Stock Holding History

Winton Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,322
Closed -$224K – 963
2022
Q2 		$224K Buy
+8,322
New +$242K 0.01% 884
2020
Q4 		– Sell
-24,180
Closed -$359K – 1339
2020
Q3 		$359K Buy
24,180
+4,779
+25% +$56K 0.01% 1197
2020
Q2 		$252K Buy
19,401
+7,374
+61% +$32.7K 0.01% 1317
2020
Q1 		$20K Sell
12,027
-20,000
-62% -$45.2K ﹤0.01% 1371
2019
Q4 		$71K Sell
32,027
-1,634
-5% -$3.79K ﹤0.01% 1498
2019
Q3 		$72K Buy
+33,661
New +$77.9K ﹤0.01% 1479

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return